查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085274

抗癌藥物市場：2026-2032 年全球市場預測，按藥物類型、給藥途徑、治療方法、癌症類型、最終用戶和分銷管道分類。

Cancer Drugs Market by Drug Type, Administration Route, Therapy Type, Cancer Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，癌症治療市場將成長至 3,382.9 億美元，複合年成長率為 10.13%。

主要市場統計數據
基準年 2025 1720.6億美元
預計年份：2026年 1887.2億美元
預測年份 2032 3382.9億美元
複合年成長率 (%) 10.13%

癌症治療市場執行摘要

癌症發生率的上升、治療週期的延長以及免疫腫瘤學、標靶治療、抗體藥物複合體、放射性藥物、細胞療法、荷爾蒙療法療法、化療和支持治療等領域技術的快速發展，正在改變癌症治療市場。根據國際癌症研究機構（IARC）統計，2022年全球新增癌症病例約2000萬例，癌症相關死亡病例約970萬例，凸顯了對有效癌症治療的持續需求。

癌症治療藥物領域的變革性變化

癌症治療領域正從廣譜細胞毒性療法轉向基於基因組分析、伴隨診斷、腫瘤特異性批准、液態生物檢體和可測量殘留病灶監測的個人化癌症治療。查核點抑制劑、激酶抑制劑、PARP抑制劑、雙特異性抗體、CAR-T療法、放射性配體療法和抗體藥物複合體正在拓展癌症治療選擇，並改變固體癌和骨髓惡性腫瘤的標準治療方案。

人工智慧對腫瘤學的累積影響

人工智慧 (AI) 透過改進標靶辨識、蛋白質建模、化合物篩檢、生物標記發現、臨床試驗匹配和安全性訊號檢測，正在加速腫瘤藥物的研發。 AI 平台可以分析基因組數據、病理圖像、診斷影像數據、電子健康記錄和真實世界資料集，從而識別對治療有反應的患者群體，並最佳化癌症療法的臨床試驗設計。

關鍵區域洞察：全球癌症治療需求

亞太地區是癌症治療領域的主要成長引擎，這得益於其龐大的患者群體、不斷完善的癌症診療基礎設施，以及中國、日本、印度、韓國和澳洲等國對標靶治療的日益普及。根據國際癌症研究機構（IARC）的數據，亞洲佔全球新增癌症病例的最大佔有率，因此，提升診斷能力、降低治療成本和實現在地化生產對於確保癌症治療的可及性至關重要。北美仍然是重要的創新中心，這得益於其在腫瘤領域的高額研發投入、美國食品藥物管理局（FDA）的加速核准程序、廣泛的生物標記檢測、積極的臨床試驗，以及對免疫療法、標靶治療和細胞療法的早期應用。

癌症治療藥物的主要群體分析

在東南亞國協，隨著成員國擴大全民健保、癌症診斷、病理檢測能力和醫院癌症治療服務，對癌症治療的需求不斷成長；然而，公立和私立醫療體系之間的可負擔性和報銷水平仍然存在差異。海灣合作理事會（GCC）市場正透過國家癌症策略、專科醫院、篩檢舉措以及採購創新癌症療法而迅速發展，尤其是在區域醫療體系優先發展精準醫療和重症癌症治療的推動下。

主要國家癌症治療藥物市場的關鍵趨勢

美國憑藉FDA的批准、NCI支持的研究、大型生物製藥公司的投資、指南的廣泛應用以及積極引入免疫腫瘤學、標靶治療、抗體藥物複合體（ADC）和細胞療法，引領全球癌症藥物創新。加拿大強調基於實證醫學的保險報銷和全國範圍內的癌症藥物評估，而墨西哥則透過醫療機構和私人管道擴大專科治療的覆蓋範圍。巴西憑藉著生物相似藥的日益普及、公共採購以及私人癌症醫療網路的建立，仍然是拉丁美洲最具影響力的癌症醫療環境。

為行業領導者提供的實用建議

產業領導者應優先考慮具有差異化優勢的腫瘤藥物，這些藥物需具備檢驗的生物標記、明確的生存終點、可控的安全性以及在早期治療、維持治療、輔助性治療、新輔助治療或聯合治療方面擁有強力的證據支持。投資於伴隨診斷、分散式臨床試驗結構、適應性試驗設計以及多元化的患者招募，可以加快法規核准流程，並增強上市申請的說服力。

調查方法

本執行摘要基於權威公共來源的二手研究，包括世界衛生組織/國際癌症研究機構的癌症負擔數據、美國食品藥品監督管理局 (FDA) 和歐洲藥品管理局 (EMA) 的監管資訊、各國癌症機構、同行評審的癌症文獻、臨床試驗註冊資訊、治療指南、藥物資訊來源以及衛生技術評估 (HTA) 出版物。市場分析與可觀察到的藥物核准趨勢、不斷更新的治療指南、生物標記的應用以及區域醫療保健可近性指標相一致。

結論

癌症藥物市場正朝著更精準、數據驅動和結果導向的時代轉型。癌症發生率的上升、生物標記的應用、免疫療法的擴展以及抗體藥物偶聯物（ADC）、雙特異性抗體、放射性配體療法、靶向蛋白水解藥物和細胞療法等先進療法的出現，正在重新定義癌症藥物領域的競爭優勢。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：抗癌藥物市場：依藥物類型分類

  • 化療
    • 烷化劑
    • 抗代謝物
    • 抗腫瘤抗生素
  • 荷爾蒙療法
  • 免疫療法
  • 標靶治療
    • 誘導細胞凋亡的藥物
    • 單株抗體
    • 蛋白酪氨酸激酶抑制劑（TKIs）

第8章：抗癌藥物市場：依給藥途徑分類

  • 肌肉內部
  • 靜脈
  • 口服
  • 皮下

第9章：癌症藥物市場：依治療類型分類

  • 聯合治療
  • 單藥治療

第10章：抗癌藥物市場：依癌症類型分類

  • 乳癌
  • 結腸癌
  • 肝癌
  • 肺癌
  • 胰臟癌
  • 攝護腺癌

第11章：抗癌藥物市場：依最終用戶分類

  • 門診部
  • 家庭醫療保健
  • 醫院和診所

第12章：抗癌藥物市場：依分銷管道分類

  • 醫院藥房
  • 零售藥房

第13章：抗癌藥物市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：抗癌藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：抗癌藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Fresenius Kabi AG
  • Getwell Oncology Pvt Ltd
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Kite Pharma, Inc by Gilead Company
  • Medivir AB
  • Merck & Co., Inc.
  • Nammi Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Taiho Pharmaceutical Co., Ltd. by Otsuka Holdings Co., Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-431B7BFFBF7B

The Cancer Drugs Market is projected to grow by USD 338.29 billion at a CAGR of 10.13% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 172.06 billion
Estimated Year [2026] USD 188.72 billion
Forecast Year [2032] USD 338.29 billion
CAGR (%) 10.13%

Cancer Drugs Market Executive Summary

The cancer drugs market is being reshaped by rising cancer incidence, longer treatment duration, and rapid innovation across immuno-oncology, targeted therapy, antibody-drug conjugates, radiopharmaceuticals, cell therapies, hormone therapy, chemotherapy, and supportive oncology care. According to the International Agency for Research on Cancer, the world recorded about 20 million new cancer cases and 9.7 million cancer deaths in 2022, underscoring sustained demand for effective oncology therapeutics.

Commercial momentum is increasingly linked to biomarker-driven treatment, real-world evidence, and accelerated regulatory pathways. Pharmaceutical leaders are prioritizing precision oncology pipelines, combination regimens, oral oncology drugs, biosimilars, and earlier-line indications to improve survival outcomes while addressing payer scrutiny around high-cost cancer medicines and equitable patient access.

Transformative Shifts in the Cancer Drug Landscape

The oncology landscape is moving from broad cytotoxic treatment toward personalized cancer therapy guided by genomic profiling, companion diagnostics, tumor-agnostic approvals, liquid biopsy, and measurable residual disease monitoring. Checkpoint inhibitors, kinase inhibitors, PARP inhibitors, bispecific antibodies, CAR-T therapies, radioligand therapies, and antibody-drug conjugates are expanding the cancer treatment arsenal and changing standards of care across solid tumors and hematologic malignancies.

At the same time, the market is becoming more evidence-intensive. Health technology assessment agencies, value-based reimbursement models, and oncology clinical pathways are increasing pressure on manufacturers to demonstrate overall survival, progression-free survival, durable response, quality-of-life improvement, safety, and cost-effectiveness in real-world populations.

Cumulative Impact of Artificial Intelligence in Oncology

Artificial intelligence is accelerating oncology drug discovery by improving target identification, protein modeling, compound screening, biomarker discovery, clinical trial matching, and safety signal detection. AI-enabled platforms can analyze genomics, pathology images, radiology scans, electronic health records, and real-world datasets to identify responder populations and refine trial design for cancer therapeutics.

The cumulative impact is strongest when AI is integrated with validated clinical evidence, regulatory-grade data governance, and oncology domain expertise. Industry adoption can shorten development cycles, improve patient stratification, support adaptive trials, strengthen pharmacovigilance, and optimize treatment sequencing while requiring careful oversight for bias, explainability, cybersecurity, transparency, and data privacy.

Key Regional Insights Across Global Cancer Drug Demand

Asia-Pacific is a major growth engine for cancer drugs due to large patient populations, expanding oncology infrastructure, and rising adoption of targeted therapies in China, Japan, India, South Korea, and Australia. IARC data show Asia accounts for the largest global cancer burden by new cases, making diagnostics expansion, affordability, and local manufacturing central to oncology access. North America remains the leading innovation hub, supported by high oncology R&D spending, FDA expedited programs, broad biomarker testing, clinical trial activity, and early uptake of immunotherapy, targeted therapy, and cell therapy.

Europe benefits from established reimbursement systems, EMA regulatory pathways, cancer screening programs, and strong clinical research networks, although access varies by country after health technology assessment review. Latin America is expanding access through public procurement, biosimilar adoption, and private oncology networks, while the Middle East is investing in specialized cancer centers, genomic medicine, and national cancer strategies. Africa faces persistent gaps in diagnosis, radiotherapy, pathology, and access to essential oncology medicines, but cancer control initiatives, diagnostics expansion, and international partnerships are improving treatment availability.

Key Group Insights for Oncology Therapeutics

ASEAN cancer drug demand is rising as member states expand universal health coverage, oncology diagnostics, pathology capacity, and hospital-based cancer care, although affordability and reimbursement remain uneven across public and private systems. GCC markets are advancing rapidly through national cancer strategies, specialty hospitals, screening initiatives, and procurement of innovative oncology therapeutics, particularly as regional health systems prioritize precision medicine and high-acuity cancer care.

The European Union is shaped by centralized EMA approvals, joint clinical assessment momentum under health technology assessment reforms, cross-border pharmacovigilance, and policy attention to equitable access to cancer medicines. BRICS countries combine large treatment-naive populations with local manufacturing, generic oncology drugs, biosimilar expansion, and expanding clinical research capacity, while G7 countries lead in high-value innovation, regulatory maturity, clinical trial density, biomarker testing, and premium oncology access. NATO member markets overlap significantly with advanced Western healthcare systems, where supply chain resilience, medicine security, and strategic procurement are increasingly important for oncology therapeutics.

Key Country Insights in the Cancer Drugs Market

The United States anchors global cancer drug innovation through FDA oncology approvals, NCI-backed research, major biopharma investment, broad guideline adoption, and strong uptake of immuno-oncology, targeted therapy, antibody-drug conjugates, and cell therapy. Canada emphasizes evidence-based reimbursement and pan-Canadian oncology evaluation, Mexico is expanding specialty access through institutional and private channels, and Brazil remains Latin America's most influential oncology environment with rising biosimilar participation, public procurement, and private cancer care networks.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are major cancer drug markets with strong clinical expertise, national treatment guidelines, and health technology assessment processes, while Russia maintains demand for essential and locally produced oncology medicines. China is scaling domestic oncology innovation, regulatory reform, clinical trial activity, and access to targeted therapies; India is driven by affordability, generic oncology drugs, biosimilars, and expanding cancer hospital networks; Japan remains a leader in precision treatment, gastric cancer research, and advanced reimbursement pathways; Australia supports high-quality reimbursement and clinical trial infrastructure; and South Korea is expanding biopharma-led oncology R&D, biosimilars, and precision oncology adoption.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated oncology assets with validated biomarkers, clear survival endpoints, manageable safety profiles, and strong evidence for earlier-line, maintenance, adjuvant, neoadjuvant, or combination use. Investment in companion diagnostics, decentralized trial capabilities, adaptive study designs, and diverse patient recruitment can improve regulatory outcomes and strengthen market access dossiers.

Companies should also build payer-ready evidence plans before pivotal trials, including real-world evidence, health economics, patient-reported outcomes, and quality-of-life measures. Strategic partnerships with AI platforms, diagnostics developers, academic cancer centers, contract research networks, manufacturing partners, and regional distributors can accelerate innovation while improving affordability and access in emerging oncology markets.

Research Methodology

This executive summary is developed using secondary research from authoritative public sources, including WHO/IARC cancer burden data, FDA and EMA regulatory information, national cancer agencies, peer-reviewed oncology literature, clinical trial registries, treatment guidelines, pharmacovigilance resources, and health technology assessment publications. Market interpretation is aligned with observable drug approval trends, treatment guideline evolution, biomarker adoption, and regional healthcare access indicators.

The methodology emphasizes triangulation across epidemiology, pipeline activity, regulatory approvals, reimbursement patterns, clinical evidence standards, access dynamics, and competitive intelligence without relying on market sizing or forecasting. Insights are reviewed for relevance to cancer drugs, oncology therapeutics, immunotherapy, targeted therapy, chemotherapy, hormone therapy, radiopharmaceuticals, biosimilars, and precision medicine to support decision-useful analysis.

Conclusion

The cancer drugs market is entering a more precise, data-driven, and outcome-focused era. Rising cancer prevalence, biomarker adoption, immunotherapy expansion, and advanced modalities such as ADCs, bispecific antibodies, radioligand therapies, targeted protein degraders, and cell therapies are redefining competitive advantage across oncology therapeutics.

Future performance will depend on clinical differentiation, affordability, regulatory agility, manufacturing reliability, and evidence generation across diverse populations. Organizations that combine scientific innovation with access strategy, AI-enabled development, diagnostic integration, and regional execution will be best positioned to lead the global oncology therapeutics market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cancer Drugs Market, by Drug Type

  • 7.1. Chemotherapy
    • 7.1.1. Alkylating Agents
    • 7.1.2. Antimetabolites
    • 7.1.3. Antitumor Antibiotics
  • 7.2. Hormone Therapy
  • 7.3. Immunotherapy
  • 7.4. Targeted Therapy
    • 7.4.1. Apoptosis-inducing Drugs
    • 7.4.2. Monoclonal Antibodies
    • 7.4.3. Tyrosine Kinase Inhibitors (TKIs)

8. Cancer Drugs Market, by Administration Route

  • 8.1. Intramuscular
  • 8.2. Intravenous
  • 8.3. Oral
  • 8.4. Subcutaneous

9. Cancer Drugs Market, by Therapy Type

  • 9.1. Combination Therapy
  • 9.2. Monotherapy

10. Cancer Drugs Market, by Cancer Type

  • 10.1. Breast Cancer
  • 10.2. Colorectal Cancer
  • 10.3. Liver Cancer
  • 10.4. Lung Cancer
  • 10.5. Pancreatic Cancer
  • 10.6. Prostate Cancer

11. Cancer Drugs Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Home Healthcare
  • 11.3. Hospitals & Clinics

12. Cancer Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Retail Pharmacy

13. Cancer Drugs Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Cancer Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cancer Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Amgen Inc.
  • 17.3. Astellas Pharma Inc
  • 17.4. AstraZeneca PLC
  • 17.5. Bayer AG
  • 17.6. BeiGene, Ltd.
  • 17.7. Bristol-Myers Squibb Company
  • 17.8. Daiichi Sankyo Company, Limited
  • 17.9. Dr. Reddy's Laboratories Ltd.
  • 17.10. Eli Lilly and Company
  • 17.11. F. Hoffmann-La Roche Ltd
  • 17.12. Fresenius Kabi AG
  • 17.13. Getwell Oncology Pvt Ltd
  • 17.14. GlaxoSmithKline plc
  • 17.15. Incyte Corporation
  • 17.16. Kite Pharma, Inc by Gilead Company
  • 17.17. Medivir AB
  • 17.18. Merck & Co., Inc.
  • 17.19. Nammi Therapeutics, Inc.
  • 17.20. Novartis AG
  • 17.21. Pfizer Inc.
  • 17.22. Sanofi S.A.
  • 17.23. Sun Pharmaceutical Industries Ltd.
  • 17.24. Taiho Pharmaceutical Co., Ltd. by Otsuka Holdings Co., Ltd.
  • 17.25. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CANCER DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CANCER DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CANCER DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIMETABOLITES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIMETABOLITES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIMETABOLITES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTITUMOR ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTITUMOR ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTITUMOR ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HORMONE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HORMONE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HORMONE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL APOPTOSIS-INDUCING DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL APOPTOSIS-INDUCING DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL APOPTOSIS-INDUCING DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TYROSINE KINASE INHIBITORS (TKIS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TYROSINE KINASE INHIBITORS (TKIS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TYROSINE KINASE INHIBITORS (TKIS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LIVER CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LIVER CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LIVER CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PANCREATIC CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PANCREATIC CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PANCREATIC CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. GCC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. GCC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. GCC CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 159. GCC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. GCC CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. GCC CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GCC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. G7 CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. G7 CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 185. G7 CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 186. G7 CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. G7 CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. G7 CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. G7 CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. NATO CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. NATO CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 195. NATO CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. NATO CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. NATO CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. NATO CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. CANADA CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. CANADA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. CANADA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. CANADA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. CANADA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. CANADA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. CANADA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. CANADA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. MEXICO CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. MEXICO CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. MEXICO CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. MEXICO CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 222. MEXICO CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 223. MEXICO CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. MEXICO CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. MEXICO CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. MEXICO CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. BRAZIL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. BRAZIL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. BRAZIL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. BRAZIL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. BRAZIL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 232. BRAZIL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. BRAZIL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. BRAZIL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. BRAZIL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED KINGDOM CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. GERMANY CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. GERMANY CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. GERMANY CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. GERMANY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. GERMANY CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 250. GERMANY CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. GERMANY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. GERMANY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. GERMANY CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. FRANCE CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. FRANCE CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. FRANCE CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 257. FRANCE CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 258. FRANCE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 259. FRANCE CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. FRANCE CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. FRANCE CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. FRANCE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. RUSSIA CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. RUSSIA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. RUSSIA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. RUSSIA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 267. RUSSIA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 268. RUSSIA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. RUSSIA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. RUSSIA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. RUSSIA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. ITALY CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. ITALY CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. ITALY CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 275. ITALY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 276. ITALY CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 277. ITALY CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. ITALY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. ITALY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. ITALY CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. SPAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 282. SPAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. SPAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 284. SPAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 285. SPAIN CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 286. SPAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. SPAIN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. SPAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. SPAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 299. INDIA CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 300. INDIA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. INDIA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 302. INDIA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 303. INDIA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 304. INDIA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. INDIA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. INDIA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. INDIA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 308. JAPAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. JAPAN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. JAPAN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 311. JAPAN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 312. JAPAN CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 313. JAPAN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. JAPAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. JAPAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 316. JAPAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 317. AUSTRALIA CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 318. AUSTRALIA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. AUSTRALIA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 320. AUSTRALIA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 321. AUSTRALIA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 322. AUSTRALIA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. AUSTRALIA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. AUSTRALIA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 325. AUSTRALIA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 326. SOUTH KOREA CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 327. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 329. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 330. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 331. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 333. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 334. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)